UAMS

iGlucose® Cellular RPM™ Shown Efficacious for Managing Diabetes Mellitus During Pregnancy

Retrieved on: 
Thursday, November 9, 2023
Women, General Health, Health, Diabetes, Medical Devices, Baby, Maternity, Consumer, Other Health, RPM, Woman, FDA, Pregnancy, Physician, University of Arkansas for Medical Sciences, Type 1, Medicine, Type 2, University, Type 2 diabetes, Vital signs, Patient, Blood, UAMS, Medical device, Medical imaging

A recently published research study from the University of Arkansas for Medical Sciences concluded that using cellular-enabled RPM™ glucose meters is valuable in managing Type 1 diabetes mellitus and Type 2 diabetes mellitus during pregnancy.

Key Points: 
  • A recently published research study from the University of Arkansas for Medical Sciences concluded that using cellular-enabled RPM™ glucose meters is valuable in managing Type 1 diabetes mellitus and Type 2 diabetes mellitus during pregnancy.
  • Participants who used the iGlucose® glucose meter demonstrated increased positive appraisal of diabetes and general life satisfaction.
  • In addition, participants scored the cellular RPM™ iGlucose® device high on both system usability and satisfaction.
  • The overall feedback on the iGlucose® glucose meter, the gold standard in cellular RPM™ glucose meters since receiving FDA approval in 2016, was positive across multiple evaluation points.

Dr. Amy Hester, Chairwoman and CEO, HD Nursing Inducted as Fellow of the American Academy of Nursing

Retrieved on: 
Tuesday, October 10, 2023
Nursing, Seniors, Hospitals, Practice Management, Other Health, Managed Care, Health, Consumer, General Health, Retirement, Health policy, Doctor of Philosophy, Mentorship, Public, Neuro, UAMS, American Academy, DC, University, RN, American Academy of Nursing, Falls, Policy, Science, Fellow, Health equity, UAMS College of Medicine, Fellows, HD, Conference, Research, Philosophy

HD Nursing , the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention, is pleased to announce that Dr. Amy Hester, PhD, RN, BC, Chairwoman and CEO, HD Nursing, has been inducted as a Fellow of the American Academy of Nursing (Academy).

Key Points: 
  • HD Nursing , the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention, is pleased to announce that Dr. Amy Hester, PhD, RN, BC, Chairwoman and CEO, HD Nursing, has been inducted as a Fellow of the American Academy of Nursing (Academy).
  • “Induction as a Fellow of the American Academy of Nursing is a profound honor, signifying my personal and professional dedication to advancing public health and healthcare equity,” says Dr. Hester.
  • “It is a privilege to join esteemed nursing leaders who have made lasting impacts in policy, research, practice and administration.
  • With over 25 years of nursing experience including over a decade of med/surge and neuro nursing followed by unit management and hospital administration, Dr. Hester is currently CEO and Chairwoman of HD Nursing.

Second Annual Arkansas Rural Health Scholarship Awarded to Jefferson Regional Nursing School Student

Retrieved on: 
Thursday, September 28, 2023
Heart, Obesity, Housing, Life, Diabetes, Registered nurse, UAMS, Interest, Hypertension, ROCK, MD, Patient, Applied science, Transport, Health, Disease, Nursing

LITTLE ROCK, Ark., Sept. 28, 2023 /PRNewswire/ -- Dr. Rhys Branman, MD, and the Little Rock Cosmetic Surgery Center team are thrilled to announce they've chosen Miranda Drake as the 2023 Arkansas Rural Health Scholarship recipient. Ms. Drake is currently enrolled at Jefferson Regional Nursing School in Pine Bluff, AR, and pursuing an Associates of Applied Sciences to become a Registered Nurse.

Key Points: 
  • Ms. Drake is currently enrolled at Jefferson Regional Nursing School in Pine Bluff, AR, and pursuing an Associates of Applied Sciences to become a Registered Nurse.
  • Dr. Branman founded the Arkansas Rural Health Scholarship to help address a growing need for quality healthcare in rural areas.
  • "This is an investment in our future healthcare providers and the health of citizens living in rural Arkansas communities," said Dr. Branman.
  • The annual Arkansas Rural Health Scholarship is a small but meaningful step in mitigating the scarcity of healthcare professionals in rural Arkansas by offering financial support to those who plan to dedicate their careers to serving patients in these high-need areas.

NFID Names Robert H. Hopkins, Jr., MD, as Medical Director

Retrieved on: 
Thursday, July 20, 2023
Vaccine, National Foundation for Infectious Diseases, Immunization, CAE, University, Hopkins, Education, Internal medicine, Human services, Public, Pediatrics, University of Arkansas for Medical Sciences, Advisory Committee, Medicine, UAMS, Human, Infection, Advisory Committee on Immunization Practices, Korea Disease Control and Prevention Agency, Growth, American College, NFID, Pharmaceutical industry, Management, Nursing, MD

BETHESDA, Md., July 20, 2023 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the appointment of Robert H. Hopkins, Jr., MD, as its new medical director.

Key Points: 
  • BETHESDA, Md., July 20, 2023 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the appointment of Robert H. Hopkins, Jr., MD, as its new medical director.
  • Hopkins succeeds William Schaffner, MD, who served NFID for many years and will continue to serve as an NFID spokesperson, lending his expertise to NFID initiatives.
  • As medical director, Hopkins will focus on the growth of NFID programs, including efforts to build vaccine confidence, address health equity issues, increase awareness of disease prevention and treatment, and strengthen NFID partner collaborations.
  • In his role as NFID medical director, Hopkins will also serve as an ex-officio member of the NFID Board of Directors and all Board-level committees.

PharmAla Awarded Research Grant by Ontario Centre for Innovation

Retrieved on: 
Friday, June 9, 2023
US Foods, CSE, University, Therapy, Drug discovery, UAMS, USFDA, MDXX, Innovation, Medicine, Psychedelic drug, Patient, Clinical research, OTC, Ontario Centre of Forensic Sciences, OCI, Conference, MDMA, Food, Pharmaceutical industry, Research

TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is excited to announce that it has been granted a research grant by the Ontario Centre for Innovation in conjunction with the University of Windsor.

Key Points: 
  • TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is excited to announce that it has been granted a research grant by the Ontario Centre for Innovation in conjunction with the University of Windsor.
  • PharmAla believes that this can be done through the aid of in-silico modelling.
  • To do that, our research team encompasses a diverse group of scientists: Preclinical researchers completing animal model research, In-Silico Drug Discovery, and very soon, Clinical Research,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “The OCI grant will allow us to bolster the funnel of our drug pipeline and develop valuable IP with non-dilutive funding.

Heifer International Receives 2023 Community Partner Award from the University of Arkansas at Little Rock

Retrieved on: 
Monday, May 15, 2023
Social responsibility, Levelling Up, Housing and Communities Committee, Communication, University, Education, Building Bridges, Little Rock, Arkansas, Qualitative Research (journal), UAMS, Heifer International, Woman, Weitbrecht Communications, CALL, Student, ROCK, American Journal, Qualitative, Social change, Faculty, Empowerment, Nursing, Dairy, Heifer

LITTLE ROCK, Ark., May 15, 2023 /PRNewswire/ -- Heifer International has been awarded the 2023 Community Partner Award from the Department of Applied Communications at the University of Arkansas at Little Rock.

Key Points: 
  • LITTLE ROCK, Ark., May 15, 2023 /PRNewswire/ -- Heifer International has been awarded the 2023 Community Partner Award from the Department of Applied Communications at the University of Arkansas at Little Rock.
  • The award recognizes Heifer International's commitment to partnering with the department's faculty and students to promote social responsibility through positive communication.
  • "We are honored to receive this award from the University of Arkansas," said Mahendra Lohani, senior vice president of Asia programs at Heifer International.
  • The Community Partner Award was presented to Heifer International at a special ceremony on the University of Arkansas campus on May 11, 2023.

University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers

Retrieved on: 
Monday, March 6, 2023
Oncology, Health, Technology, Genetics, Software, Biotechnology, Bone marrow, Sophia Genetics, GENETICS, Artificial intelligence, Tumors of the hematopoietic and lymphoid tissues, Leukemia, Hematology, Medicine, Sophia, Patient, Multiple myeloma, UAMS, University of Arkansas for Medical Sciences, University, Lymphoma, NGS, Ponce Health Sciences University, Pharmaceutical industry, Medical imaging

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research.

Key Points: 
  • SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research.
  • As the only health sciences university in the state of Arkansas and the state’s largest public employer, UAMS is a cornerstone of medical research and treatment for the state.
  • “Our mission at SOPHiA GENETICS is to democratize data-driven medicine, making it more accessible to all,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS.
  • The SOPHiA DDM™ for Blood Cancers solution will put increased data at the fingertips of clinical researchers.”
    For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on Twitter , LinkedIn , Facebook , and Instagram .

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, UAMS, Safety, Pharmacology, University, Toxicology, Research, CSE, ABA, University of Arkansas School of Law, GMP, NCE, Hyperthermia, MDMA, Cardiotoxicity, PCT, Medicine, ALA, Patent Cooperation Treaty, MBDB, Pharmaceutical industry, Dietary supplement

VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs).
  • The application claims priority to and benefit of a United States provisional patent application filed on August 20, 2021.
  • This PCT application disclosed novel compositions of MDMA and analogs thereof, which may be used to alleviate the known side effects of MDMA while retaining its efficacy.
  • The PharmAla Patent Application also countenances the composition of 3 novel compositions of 1,3-benzodioxolyl-N-methylbutanamine (MBDB), a lesser-known analog of MDMA, which also presents an improved toxicology profile based on animal models; PharmAla refers to these compositions as the ABA series.

Large-scale, peer-reviewed study quantifies multiple devastating patient harms associated with blood culture contamination and most significantly, a 74% increase in risk of in-hospital patient mortality

Retrieved on: 
Tuesday, January 24, 2023
BMI, Safety, Vancomycin, University, Blood culture, University of Arkansas, Medical Center, Invention, Emergency department, Medical director, Culture, Entrepreneurship, Associate, Infection, Fungal infection, Infection Control & Hospital Epidemiology, Hospital, Acute kidney injury, Risk factor, Patient safety, FDA, Growth, UAMS, Antimicrobial stewardship, Length of stay, Patient, Sepsis, Risk, Body mass index, Mortality, HAI, Magnolia, Clostridioides difficile infection, CDI, Medicine, Pharmaceutical industry, Nursing

SEATTLE, Jan. 24, 2023 /PRNewswire/ -- Magnolia Medical Technologies, Inc. ("Magnolia Medical"), inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®), the only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination for sepsis testing accuracy1, today shared the publication of recent clinical results from the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas. This four-year retrospective analysis examined the clinical and financial impacts of blood culture contamination on patient safety, outcomes, and in-hospital patient mortality.

Key Points: 
  • This four-year retrospective analysis examined the clinical and financial impacts of blood culture contamination on patient safety, outcomes, and in-hospital patient mortality.
  • Blood culture is one of the most frequently performed diagnostic tests in U.S. hospitals with an estimated 58 million tests each year.
  • However, positive blood culture results are frequently wrong, with approximately 40% of positive results returning a false-positive result due to contamination.
  • "It is imperative for hospital systems to make decreasing blood culture contamination a priority to improve safety for patients under our care.

Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences

Retrieved on: 
Tuesday, December 13, 2022
Baptist Health, Contessa, Translational Research Institute, Rehabilitation, Student, Palliative care, ROCK, Eating, Ageing, The Neurosciences Institute, Trauma, MBA, Investment, Arkansas Children's Hospital, Information, Modern Healthcare, Veterans Health Administration, Terrorism, Hospital, Home, Star, UAMS, QPC, Digital health, Level 1, Health, Winthrop, Lexington VA Medical Center, University of Arkansas for Medical Sciences, University, Patient, Hospice, Physician, Failure, Northwestern Health Sciences University, Government, Climate change, Anatomical pathology, The Last Best Place, Conditional sentence, Health care, Public health, Partnership, Medicine, Health insurance, Nursing, Pharmacy, Medicare, Central Arkansas, Amedisys

and NASHVILLE, Tenn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences (UAMS) to provide home health services in Searcy and Little Rock.

Key Points: 
  • and NASHVILLE, Tenn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences (UAMS) to provide home health services in Searcy and Little Rock.
  • This joint venture is part of the partnership between UAMS, Amedisys and Contessa, an Amedisys company, to offer patients a full spectrum of medical care in the comfort and convenience of their own homes through UAMS Health Comprehensive Care at Home.
  • Home health services will operate as UAMS Health Home Health across 12 counties in Central Arkansas.
  • Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States.